Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

Bartlett J, Canney P, Campbell A, Cameron D, Donovan J, Dunn J, Earl H, Francis A, Hall P, Harmer V, Higgins H, Hillier L, Hulme C, Hughes-Davies L, Makris A, Morgan A, McCabe C, Pinder S, Poole C, Rea D, Stallard N, Stein R.

Clin Oncol (R Coll Radiol). 2013 Feb;25(2):109-16. doi: 10.1016/j.clon.2012.10.005. Epub 2012 Dec 23. Review.

PMID:
23267818
2.

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.

Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A; OPTIMA Trial Management Group.

Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201. doi: 10.3310/hta20100.

3.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
4.
5.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
6.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

7.

Adjuvant chemotherapy in early breast cancer.

Ejlertsen B.

Dan Med J. 2016 May;63(5). pii: B5222. Review.

PMID:
27127018
8.

Adjuvant therapy for breast cancer.

[No authors listed]

NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. Review.

PMID:
11512506
9.

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.

10.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
11.

WITHDRAWN: Tamoxifen for early breast cancer.

Clarke MJ.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000486. doi: 10.1002/14651858.CD000486.pub2. Review.

PMID:
18843611
12.

Tamoxifen for early breast cancer.

Early Breast Cancer Trialists' Collaborative Group.

Cochrane Database Syst Rev. 2001;(1):CD000486. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD000486.

PMID:
11279694
13.

WITHDRAWN: Multi-agent chemotherapy for early breast cancer.

Clarke MJ.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. Review.

PMID:
18843612
14.

Multi-agent chemotherapy for early breast cancer.

Early Breast Cancer Trialists' Collaborative Group.

Cochrane Database Syst Rev. 2002;(1):CD000487. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD000487.

PMID:
11869577
15.

Adjuvant endocrine therapy for premenopausal women with breast cancer.

Puhalla S, Brufsky A, Davidson N.

Breast. 2009 Oct;18 Suppl 3:S122-30. doi: 10.1016/S0960-9776(09)70286-3. Review.

16.

Progress in adjuvant chemotherapy for breast cancer: an overview.

Anampa J, Makower D, Sparano JA.

BMC Med. 2015 Aug 17;13:195. doi: 10.1186/s12916-015-0439-8. Review.

17.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
18.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
19.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
20.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

Supplemental Content

Support Center